HN1999000089A - Formulaciones de ziprasidona - Google Patents

Formulaciones de ziprasidona

Info

Publication number
HN1999000089A
HN1999000089A HN1999000089A HN1999000089A HN1999000089A HN 1999000089 A HN1999000089 A HN 1999000089A HN 1999000089 A HN1999000089 A HN 1999000089A HN 1999000089 A HN1999000089 A HN 1999000089A HN 1999000089 A HN1999000089 A HN 1999000089A
Authority
HN
Honduras
Prior art keywords
formulations
ziprasidone
ziprasidone formulations
ziprasidona
present
Prior art date
Application number
HN1999000089A
Other languages
English (en)
Inventor
Pfizer Products Inc
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22216447&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN1999000089(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HN1999000089A publication Critical patent/HN1999000089A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Abstract

LA PRESENTE INVENCION SE REFIERE A FORMULACIONES DE ZIPRASIDONA
HN1999000089A 1998-06-15 1999-06-04 Formulaciones de ziprasidona HN1999000089A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8922998P 1998-06-15 1998-06-15

Publications (1)

Publication Number Publication Date
HN1999000089A true HN1999000089A (es) 1999-11-03

Family

ID=22216447

Family Applications (1)

Application Number Title Priority Date Filing Date
HN1999000089A HN1999000089A (es) 1998-06-15 1999-06-04 Formulaciones de ziprasidona

Country Status (45)

Country Link
US (1) US6150366A (es)
EP (1) EP0965343B1 (es)
JP (2) JP3441676B2 (es)
KR (1) KR100338915B1 (es)
CN (1) CN1307994C (es)
AP (1) AP1216A (es)
AR (1) AR015553A1 (es)
AT (1) ATE240732T1 (es)
AU (1) AU753820B2 (es)
BG (1) BG64691B1 (es)
BR (1) BR9902268A (es)
CA (1) CA2274338C (es)
CO (1) CO5070579A1 (es)
CY (1) CY2003002I1 (es)
CZ (1) CZ297954B6 (es)
DE (1) DE69908021T2 (es)
DK (1) DK0965343T3 (es)
EA (1) EA002223B1 (es)
ES (1) ES2197581T3 (es)
GT (1) GT199900080A (es)
HK (1) HK1024184A1 (es)
HN (1) HN1999000089A (es)
HR (1) HRP990193B1 (es)
HU (1) HU226487B1 (es)
ID (1) ID23546A (es)
IL (1) IL130424A (es)
IS (1) IS2182B (es)
MA (1) MA26647A1 (es)
MY (1) MY121397A (es)
NO (1) NO316713B1 (es)
NZ (1) NZ336271A (es)
OA (1) OA11064A (es)
PA (1) PA8475601A1 (es)
PE (1) PE20000632A1 (es)
PL (2) PL195209B1 (es)
PT (1) PT965343E (es)
RS (1) RS49611B (es)
SG (1) SG77243A1 (es)
SI (1) SI0965343T1 (es)
SK (1) SK286245B6 (es)
TR (1) TR199901379A2 (es)
TW (1) TW590774B (es)
UA (1) UA59383C2 (es)
UY (1) UY25649A1 (es)
ZA (1) ZA993938B (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
WO2000072847A1 (en) * 1999-05-27 2000-12-07 Pfizer Products Inc. Ziprasidone suspension
US7175855B1 (en) 1999-05-27 2007-02-13 Pfizer Inc. Ziprasidone suspension
CN1407884B (zh) 1999-10-29 2012-06-20 欧罗赛铁克股份有限公司 控释氢可酮制剂
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US6733783B2 (en) 2000-10-30 2004-05-11 Euro-Celtique S.A. Controlled release hydrocodone formulations
UY27668A1 (es) * 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
CN1320886C (zh) * 2002-05-17 2007-06-13 杜克大学 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
WO2004050655A1 (en) * 2002-12-04 2004-06-17 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride
US7488729B2 (en) * 2002-12-04 2009-02-10 Dr. Reddy's Laboratories Limited Polymorphic forms of ziprasidone and its hydrochloride salt and process for preparation thereof
AU2003245027A1 (en) * 2003-04-11 2004-11-01 Hetero Drugs Limited Novel crystalline forms of ziprasidone hydrochloride
JP4343948B2 (ja) * 2003-04-29 2009-10-14 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少に影響を及ぼすための組成物
KR20060015750A (ko) * 2003-06-03 2006-02-20 테바 파마슈티컬 인더스트리즈 리미티드 지프라시돈 ＨＣｌ의 다형 형태 및 그 제조 방법
US20050049295A1 (en) * 2003-06-12 2005-03-03 Dr. Reddy's Laboratories Limited Process for the preparation of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1piperazinyl) ethyl)-6-chloro-1, 3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride) and its intermediate
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
EP1628973A2 (en) * 2003-10-24 2006-03-01 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
WO2005054235A1 (en) * 2003-11-28 2005-06-16 Wockhardt Limited Process for the preparing ziprasidone monohydrochloride hydrate
US20050197347A1 (en) * 2003-12-18 2005-09-08 Judith Aronhime Polymorphic form B2 of ziprasidone base
CA2552126A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Ziprasidone formulations
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US7429580B2 (en) * 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
PT1720867E (pt) * 2004-02-27 2010-01-28 Ranbaxy Lab Ltd Processo para a preparação de ziprasidona
MXPA06012685A (es) * 2004-05-03 2007-01-16 Univ Duke Composiciones para afectar la perdida de peso.
WO2005107719A2 (en) * 2004-05-06 2005-11-17 Sandoz Ag Pharmaceutical composition comprising hydrophobic drug having improved solubility
CA2467538C (en) * 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
WO2005123086A2 (en) * 2004-06-11 2005-12-29 Dr. Reddy's Laboratories Ltd. Ziprasidone dosage form
CA2471219A1 (en) * 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US9044503B2 (en) * 2004-08-27 2015-06-02 University Of Kentucky Research Foundation Amyloid peptide inactivating enzyme to treat alzheimer's disease peripherally
JP2008511607A (ja) * 2004-08-31 2008-04-17 ファイザー・プロダクツ・インク 低溶解性薬物および重合体を含む医薬投与剤形
EP1827374B1 (en) * 2004-11-16 2014-11-05 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
US20080268034A1 (en) * 2005-01-07 2008-10-30 Girish Karanth Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
US7749529B2 (en) * 2005-02-08 2010-07-06 Ash Access Technology, Inc. Catheter lock solution comprising citrate and a paraben
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) * 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
EP1858892A1 (en) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd Anhydrous ziprasidone mesylate and a process for its preparation
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
JP2008538751A (ja) * 2005-04-13 2008-11-06 ファイザー・プロダクツ・インク ナノ粒子組成物を持続放出するための注射用デポ製剤および方法
TW200716091A (en) * 2005-04-22 2007-05-01 Wyeth Corp New therapeutic combinations for the treatment or prevention of psychotic disorders
PL1884242T3 (pl) 2005-05-26 2013-09-30 Sumitomo Dainippon Pharma Co Ltd Kompozycja farmaceutyczna zawierająca lurasidon
JP2008546781A (ja) * 2005-06-20 2008-12-25 エラン・ファルマ・インターナショナル・リミテッド アリール−複素環式化合物を含んでなるナノ粒状及び制御放出の組成物
CA2613474A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
PL2135603T3 (pl) 2005-11-22 2013-09-30 Orexigen Therapeutics Inc Kompozycje i sposoby zwiększania wrażliwości na insulinę
US20070148237A1 (en) * 2005-11-28 2007-06-28 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
PL379569A1 (pl) * 2006-04-28 2007-10-29 Pliva Kraków Zakłady Farmaceutyczne Spółka Akcyjna Sposób wytwarzania kompozycji farmaceutycznej zawierającej substancję aktywną ziprasidone lub jego farmaceutycznie dopuszczalną sól zwiększający rozpuszczalność i biodostępność tego leku, kompozycja farmaceutyczna i zastosowanie hydrofilowych substancji pomocniczych
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP1892243A1 (en) * 2006-08-02 2008-02-27 KRKA, tovarna zdravil, d.d., Novo mesto Polymorphic forms of ziprasidone sulphate salts
EP1889844A3 (en) * 2006-08-02 2008-03-05 Krka Polymorphic forms of ziprasidone sulphates
KR101735466B1 (ko) 2006-11-09 2017-05-15 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
CA2668885C (en) 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
CN101677568A (zh) * 2007-05-18 2010-03-24 赛多斯有限责任公司 齐拉西酮制剂
EP2197446A4 (en) * 2007-08-31 2012-01-25 Reddys Lab Ltd Dr PREPARATION OF HYDROCHLORIDE OF ZIPRASIDONE MONOHYDRATE
WO2009116085A2 (en) * 2008-03-11 2009-09-24 Alkem Laboratories Ltd. An improved process for the preparation of ziprasidone
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
DE102008045854A1 (de) 2008-09-05 2010-03-11 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Partikel aus Ziprasidone und einem Sprengmittel enthaltende Pharmazeutische Zusammensetzung
CA2937222C (en) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
EP2340834A1 (en) 2009-12-30 2011-07-06 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Enhanced Solubility of Ziprasidone
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
ES2767848T3 (es) 2010-02-25 2020-06-18 Bristol Myers Squibb Holdings Ireland Formulaciones de apixabán
WO2011148253A2 (en) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Solid dosage forms of antipsychotics
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神***病を処置するための方法および組成物
US11273158B2 (en) 2018-03-05 2022-03-15 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
DE4141268A1 (de) * 1991-12-14 1993-06-17 Merck Patent Gmbh Pharmazeutische zubereitung
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5338846A (en) * 1992-08-26 1994-08-16 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) * 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
ATE254600T1 (de) * 1996-02-13 2003-12-15 Pfizer Prodrogen von 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl ethyl)-6-chloro-1,3-dihydro-2h-indol- 2-on
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit

Also Published As

Publication number Publication date
EA199900467A3 (ru) 2000-04-24
TR199901379A2 (xx) 2000-01-21
NO316713B1 (no) 2004-04-13
EP0965343B1 (en) 2003-05-21
PT965343E (pt) 2003-08-29
BG64691B1 (bg) 2005-12-30
EA199900467A2 (ru) 1999-12-29
BG103489A (en) 2000-07-31
SI0965343T1 (en) 2003-10-31
CO5070579A1 (es) 2001-08-28
PL195209B1 (pl) 2007-08-31
JP2002003492A (ja) 2002-01-09
HRP990193B1 (en) 2003-08-31
CA2274338C (en) 2003-04-15
SK286245B6 (sk) 2008-06-06
ATE240732T1 (de) 2003-06-15
JP3441676B2 (ja) 2003-09-02
NO992892L (no) 1999-12-16
DK0965343T3 (da) 2003-08-04
NO992892D0 (no) 1999-06-14
GT199900080A (es) 2000-11-29
AP9901579A0 (en) 1999-06-30
IS5079A (is) 1999-12-16
CZ212799A3 (cs) 2000-09-13
CA2274338A1 (en) 1999-12-15
ID23546A (id) 2000-05-04
AP1216A (en) 2003-10-19
HUP9901960A2 (hu) 2000-08-28
CN1307994C (zh) 2007-04-04
PL195606B1 (pl) 2007-10-31
ZA993938B (en) 2000-12-14
CN1242987A (zh) 2000-02-02
HUP9901960A3 (en) 2000-09-28
HK1024184A1 (en) 2000-10-05
KR100338915B1 (ko) 2002-05-30
CZ297954B6 (cs) 2007-05-09
HU226487B1 (en) 2009-03-02
UY25649A1 (es) 2000-02-23
ES2197581T3 (es) 2004-01-01
DE69908021D1 (de) 2003-06-26
MA26647A1 (fr) 2004-12-20
SK76999A3 (en) 2000-12-11
IL130424A0 (en) 2000-06-01
AU753820B2 (en) 2002-10-31
CY2003002I1 (el) 2009-11-04
SG77243A1 (en) 2000-12-19
HU9901960D0 (en) 1999-08-30
MY121397A (en) 2006-01-28
PA8475601A1 (es) 2000-09-29
IS2182B (is) 2006-12-15
PE20000632A1 (es) 2000-07-26
YU27199A (sh) 2002-12-10
UA59383C2 (uk) 2003-09-15
DE69908021T2 (de) 2003-11-27
JP4187423B2 (ja) 2008-11-26
EP0965343A2 (en) 1999-12-22
EA002223B1 (ru) 2002-02-28
US6150366A (en) 2000-11-21
NZ336271A (en) 2000-10-27
KR20000006143A (ko) 2000-01-25
AU3398399A (en) 1999-12-23
JP2000007566A (ja) 2000-01-11
IL130424A (en) 2003-10-31
TW590774B (en) 2004-06-11
AR015553A1 (es) 2001-05-02
BR9902268A (pt) 2000-05-02
PL333737A1 (en) 1999-12-20
EP0965343A3 (en) 2000-02-23
OA11064A (en) 2002-03-13
RS49611B (sr) 2007-06-04
HRP990193A2 (en) 2000-02-29

Similar Documents

Publication Publication Date Title
HN1999000089A (es) Formulaciones de ziprasidona
HN1999000066A (es) Formulaciones farmaceuticas
HN2001000139A (es) Interleuquina 2 estabilizada
HN1997000166A (es) 1-arilpirazoles plaguicidas
HN1998000086A (es) Derivados de 9 - desofo - 9 aza - 9a - homoeritromicina a - c - 4 sustituidos.
HN1997000023A (es) Derivados de lactama
HN1998000011A (es) Derivados de acidos arilsulfonilaminohidroxamicos
HN1998000036A (es) Compuesto de pirazina
HN1997000090A (es) Compuestos de piridilpirrol
HN1998000168A (es) Derivados de la tienapirimidina y de la tienapiridina utiles como agentes anticancerigenos.
HN1999000155A (es) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas
HN1999000125A (es) Nuevos derivados sustituidos del pirazol
HN1998000030A (es) 2-amino-6-(4fenoxi-2-sustituido)-piridinas sustituidas
HN1998000106A (es) Composiciones parenterales de alatroflaxacino
HN1998000199A (es) Agentes terapeuticos
HN1998000045A (es) Composiciones farmaceuticas
HN1998000102A (es) Composiciones solubilizadas de sertralina
HN1999000008A (es) gen de streptomices
HN1998000165A (es) Polimorfos dofetilina
HN1999000202A (es) Derivados de higromicina
HN1997000119A (es) Formulaciones repelente
HN1999000038A (es) Nuevos compuestos fungicidas
HN1998000145A (es) Formulaciones parasiticidas
HN1998000130A (es) Derivados de pirimidin-2-oxi-4-ona y pirimidin -2-oxi-4-tiona
HN1998000006A (es) Derivados de sulfonil urea